VIVUS Announces Suit Dismissal and 4 Healthcare Stocks in Demand
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares saw a huge boost following Simeonidis’ informal physician polling which revealed that 70 to 75 percent of doctors attending the Obesity Society meeting stated that they would prescribe Belviq or Qsymia.
Insmed, Inc. (NASDAQ:INSM) saw an increase of 18 percent closing at $6.36 Friday on news of RA Capital’s 7.9% stake in the company this week.
VIVUS (NASDAQ:VVUS) announced the dismissal of a putative class action lawsuit that was named Kovtun v. Vivus, Inc., et al., Case No. 4:10-CV-04957-PJH, and filed in November 2010 against the company and two of its officers alleging securities fraud. On September 27, 2012, Honorable Phyllis J. Hamilton of the U.S. District Court for the Northern District of California granted, with prejudice, VIVUS’s motion for the dismissal of all claims against VIVUS and its officers for failing to state a claim. In October 2011, Judge Hamilton dismissed an earlier version of the Plaintiffs’ complaint, but granted the plaintiffs leave to file an amended complaint, which has now been dismissed by Judge Hamilton without leave to amend.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Dendreon Corporation (NASDAQ:DNDN) will announce its latest quarterly results on October 30th to shareholders. The company conference call will be hosted at 9 am.
Pfizer (NYSE:PFE) announced that its vaccine for streptococcus pneumonia, Prevenar 13, has met the main goal of a late-stage trial, assisting in the support of a European regulatory application for the marketing of the drug in the 18-49 age group. Wall Street applauded the news, and the stock was pushed to a five-year high of $25.59.
Don’t Miss: LifeLock: Weak IPO Not Surprising.